The comparative effects of sacubitril/valsartan versus enalapril on pulmonary hypertension due to heart failure with a reduced ejection fraction
Abstract The purpose of this study was to investigate the effects of sacubitril/valsartan on right ventricular (RV) function in patients with pulmonary hypertension (PH) due to heart failure with reduced ejection fraction (HFrEF). We prospectively enrolled patients with HFrEF‐induced PH admitted to...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-07-01
|
| Series: | Pulmonary Circulation |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/pul2.12034 |
| _version_ | 1811205246920163328 |
|---|---|
| author | Ying Zhao Li‐guo Tian Li‐xin Zhang Tao Ma Liang Di Yan‐bo Wang Xin‐shun Gu Dan‐dan Wang Shang Gao Haiyan Wang |
| author_facet | Ying Zhao Li‐guo Tian Li‐xin Zhang Tao Ma Liang Di Yan‐bo Wang Xin‐shun Gu Dan‐dan Wang Shang Gao Haiyan Wang |
| author_sort | Ying Zhao |
| collection | DOAJ |
| description | Abstract The purpose of this study was to investigate the effects of sacubitril/valsartan on right ventricular (RV) function in patients with pulmonary hypertension (PH) due to heart failure with reduced ejection fraction (HFrEF). We prospectively enrolled patients with HFrEF‐induced PH admitted to the Department of Cardiology between August 2018 and December 2019. Patients were randomized to receive oral treatment with sacubitril/valsartan or enalapril. Epidemiological data were recorded before treatment. Echocardiography was performed at admission and 6 months of follow‐up, and all parameters were compared. Major adverse cardiac events (MACEs) were compared between baseline and 6 months follow‐up. There were no significant differences in the baseline characteristics between the two groups. After 6 months of treatment, both treatment groups improved the following parameters from baseline (mean ± SD): left atrium, left ventricle, the left ventricular ejection function (LVEF), RV systolic function (the tricuspid annular plane systolic excursion [TAPSE], the systolic pulmonary artery pressure [sPAP], and TAPSE/sPAP). After 6 months, sacubitril/valsartan improved significantly the following parameters compared with enalapril (all p < 0.05): LVEF (47.07 ± 6.93% vs. 43.47 ± 7.95%); TAPSE (15.33 ± 1.31 vs. 14.78 ± 1.36 mm); sPAP (36.76 ± 14.32 vs. 42.26 ± 12.07 mmHg); and TAPSE/sPAP ratio (0.50 ± 0.23 vs. 0.39 ± 0.14), respectively. There was no difference in readmissions due to recurrent heart failure. Sacubitril/valsartan seems to provide more beneficial effects among patients with HFrEF‐induced PH to improve RV function, along with a decrease in pulmonary pressure. |
| first_indexed | 2024-04-12T03:28:50Z |
| format | Article |
| id | doaj.art-ac22841f02d74e5f844430dba32bfeeb |
| institution | Directory Open Access Journal |
| issn | 2045-8940 |
| language | English |
| last_indexed | 2024-04-12T03:28:50Z |
| publishDate | 2022-07-01 |
| publisher | Wiley |
| record_format | Article |
| series | Pulmonary Circulation |
| spelling | doaj.art-ac22841f02d74e5f844430dba32bfeeb2022-12-22T03:49:37ZengWileyPulmonary Circulation2045-89402022-07-01123n/an/a10.1002/pul2.12034The comparative effects of sacubitril/valsartan versus enalapril on pulmonary hypertension due to heart failure with a reduced ejection fractionYing Zhao0Li‐guo Tian1Li‐xin Zhang2Tao Ma3Liang Di4Yan‐bo Wang5Xin‐shun Gu6Dan‐dan Wang7Shang Gao8Haiyan Wang9Department of Cardiology the Hai‐gang Hospital of Qinhuangdao Qinhuangdao Hebei ChinaDepartment of Cardiology the Hai‐gang Hospital of Qinhuangdao Qinhuangdao Hebei ChinaDepartment of Cardiology the Hai‐gang Hospital of Qinhuangdao Qinhuangdao Hebei ChinaDepartment of Cardiology the Hai‐gang Hospital of Qinhuangdao Qinhuangdao Hebei ChinaDepartment of Cardiology the Hai‐gang Hospital of Qinhuangdao Qinhuangdao Hebei ChinaDepartment of Cardiology the Second Hospital of Hebei Medical University Shijiazhuang Hebei ChinaDepartment of Cardiology the Second Hospital of Hebei Medical University Shijiazhuang Hebei ChinaDepartment of Cardiology the Hai‐gang Hospital of Qinhuangdao Qinhuangdao Hebei ChinaDepartment of Cardiology the Hai‐gang Hospital of Qinhuangdao Qinhuangdao Hebei ChinaDepartment of Cardiology Handan Central Hospital Handan Hebei ChinaAbstract The purpose of this study was to investigate the effects of sacubitril/valsartan on right ventricular (RV) function in patients with pulmonary hypertension (PH) due to heart failure with reduced ejection fraction (HFrEF). We prospectively enrolled patients with HFrEF‐induced PH admitted to the Department of Cardiology between August 2018 and December 2019. Patients were randomized to receive oral treatment with sacubitril/valsartan or enalapril. Epidemiological data were recorded before treatment. Echocardiography was performed at admission and 6 months of follow‐up, and all parameters were compared. Major adverse cardiac events (MACEs) were compared between baseline and 6 months follow‐up. There were no significant differences in the baseline characteristics between the two groups. After 6 months of treatment, both treatment groups improved the following parameters from baseline (mean ± SD): left atrium, left ventricle, the left ventricular ejection function (LVEF), RV systolic function (the tricuspid annular plane systolic excursion [TAPSE], the systolic pulmonary artery pressure [sPAP], and TAPSE/sPAP). After 6 months, sacubitril/valsartan improved significantly the following parameters compared with enalapril (all p < 0.05): LVEF (47.07 ± 6.93% vs. 43.47 ± 7.95%); TAPSE (15.33 ± 1.31 vs. 14.78 ± 1.36 mm); sPAP (36.76 ± 14.32 vs. 42.26 ± 12.07 mmHg); and TAPSE/sPAP ratio (0.50 ± 0.23 vs. 0.39 ± 0.14), respectively. There was no difference in readmissions due to recurrent heart failure. Sacubitril/valsartan seems to provide more beneficial effects among patients with HFrEF‐induced PH to improve RV function, along with a decrease in pulmonary pressure.https://doi.org/10.1002/pul2.12034heart failure with reduced ejection fractionPH‐LHDright ventriclesacubitril/valsartanTAPSE/sPAP |
| spellingShingle | Ying Zhao Li‐guo Tian Li‐xin Zhang Tao Ma Liang Di Yan‐bo Wang Xin‐shun Gu Dan‐dan Wang Shang Gao Haiyan Wang The comparative effects of sacubitril/valsartan versus enalapril on pulmonary hypertension due to heart failure with a reduced ejection fraction Pulmonary Circulation heart failure with reduced ejection fraction PH‐LHD right ventricle sacubitril/valsartan TAPSE/sPAP |
| title | The comparative effects of sacubitril/valsartan versus enalapril on pulmonary hypertension due to heart failure with a reduced ejection fraction |
| title_full | The comparative effects of sacubitril/valsartan versus enalapril on pulmonary hypertension due to heart failure with a reduced ejection fraction |
| title_fullStr | The comparative effects of sacubitril/valsartan versus enalapril on pulmonary hypertension due to heart failure with a reduced ejection fraction |
| title_full_unstemmed | The comparative effects of sacubitril/valsartan versus enalapril on pulmonary hypertension due to heart failure with a reduced ejection fraction |
| title_short | The comparative effects of sacubitril/valsartan versus enalapril on pulmonary hypertension due to heart failure with a reduced ejection fraction |
| title_sort | comparative effects of sacubitril valsartan versus enalapril on pulmonary hypertension due to heart failure with a reduced ejection fraction |
| topic | heart failure with reduced ejection fraction PH‐LHD right ventricle sacubitril/valsartan TAPSE/sPAP |
| url | https://doi.org/10.1002/pul2.12034 |
| work_keys_str_mv | AT yingzhao thecomparativeeffectsofsacubitrilvalsartanversusenalaprilonpulmonaryhypertensionduetoheartfailurewithareducedejectionfraction AT liguotian thecomparativeeffectsofsacubitrilvalsartanversusenalaprilonpulmonaryhypertensionduetoheartfailurewithareducedejectionfraction AT lixinzhang thecomparativeeffectsofsacubitrilvalsartanversusenalaprilonpulmonaryhypertensionduetoheartfailurewithareducedejectionfraction AT taoma thecomparativeeffectsofsacubitrilvalsartanversusenalaprilonpulmonaryhypertensionduetoheartfailurewithareducedejectionfraction AT liangdi thecomparativeeffectsofsacubitrilvalsartanversusenalaprilonpulmonaryhypertensionduetoheartfailurewithareducedejectionfraction AT yanbowang thecomparativeeffectsofsacubitrilvalsartanversusenalaprilonpulmonaryhypertensionduetoheartfailurewithareducedejectionfraction AT xinshungu thecomparativeeffectsofsacubitrilvalsartanversusenalaprilonpulmonaryhypertensionduetoheartfailurewithareducedejectionfraction AT dandanwang thecomparativeeffectsofsacubitrilvalsartanversusenalaprilonpulmonaryhypertensionduetoheartfailurewithareducedejectionfraction AT shanggao thecomparativeeffectsofsacubitrilvalsartanversusenalaprilonpulmonaryhypertensionduetoheartfailurewithareducedejectionfraction AT haiyanwang thecomparativeeffectsofsacubitrilvalsartanversusenalaprilonpulmonaryhypertensionduetoheartfailurewithareducedejectionfraction AT yingzhao comparativeeffectsofsacubitrilvalsartanversusenalaprilonpulmonaryhypertensionduetoheartfailurewithareducedejectionfraction AT liguotian comparativeeffectsofsacubitrilvalsartanversusenalaprilonpulmonaryhypertensionduetoheartfailurewithareducedejectionfraction AT lixinzhang comparativeeffectsofsacubitrilvalsartanversusenalaprilonpulmonaryhypertensionduetoheartfailurewithareducedejectionfraction AT taoma comparativeeffectsofsacubitrilvalsartanversusenalaprilonpulmonaryhypertensionduetoheartfailurewithareducedejectionfraction AT liangdi comparativeeffectsofsacubitrilvalsartanversusenalaprilonpulmonaryhypertensionduetoheartfailurewithareducedejectionfraction AT yanbowang comparativeeffectsofsacubitrilvalsartanversusenalaprilonpulmonaryhypertensionduetoheartfailurewithareducedejectionfraction AT xinshungu comparativeeffectsofsacubitrilvalsartanversusenalaprilonpulmonaryhypertensionduetoheartfailurewithareducedejectionfraction AT dandanwang comparativeeffectsofsacubitrilvalsartanversusenalaprilonpulmonaryhypertensionduetoheartfailurewithareducedejectionfraction AT shanggao comparativeeffectsofsacubitrilvalsartanversusenalaprilonpulmonaryhypertensionduetoheartfailurewithareducedejectionfraction AT haiyanwang comparativeeffectsofsacubitrilvalsartanversusenalaprilonpulmonaryhypertensionduetoheartfailurewithareducedejectionfraction |